Stock Analysis on Net
Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Common-Size Balance Sheet: Assets
Quarterly Data

AbbVie Inc., common-size consolidated balance sheet: assets (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Cash and equivalents 9.51 9.75 6.47 4.99 6.63 8.37 5.95 4.26 6.65 8.18 5.78 6.48 5.61 5.27 4.02 45.11 44.80 17.91 9.05 8.63
Short-term investments 0.00 0.00 0.01 0.01 0.02 0.03 1.01 1.03 0.06 0.05 0.04 0.01 0.02 0.04 0.02 0.00 0.00 0.00 0.43 0.58
Accounts receivable, net 8.28 8.38 8.49 8.53 8.11 7.60 7.85 7.49 6.81 6.23 6.70 6.37 5.86 5.62 5.59 6.98 6.09 9.30 9.59 10.01
Inventories 3.04 2.92 3.00 2.85 2.58 2.24 2.37 2.43 2.13 2.08 2.29 2.17 2.20 2.32 2.71 2.02 2.03 3.25 3.32 3.00
Prepaid expenses and other 3.66 3.33 3.35 3.31 3.17 3.23 3.15 3.30 3.41 2.91 2.77 2.61 2.37 2.12 1.87 2.64 2.64 3.47 4.04 3.18
Current assets 24.50% 24.39% 21.31% 19.69% 20.51% 21.49% 20.32% 18.51% 19.06% 19.45% 17.57% 17.65% 16.05% 15.38% 14.22% 56.75% 55.57% 33.93% 26.43% 25.39%
Investments 0.23 0.20 0.21 0.19 0.17 0.17 0.17 0.18 0.19 0.18 0.18 0.20 0.19 0.16 0.15 0.09 0.10 0.22 2.58 2.60
Property and equipment, net 3.70 3.62 3.65 3.66 3.56 3.46 3.46 3.54 3.49 3.45 3.49 3.45 3.49 3.33 3.28 3.25 3.32 4.87 5.04 5.04
Intangible assets, net 41.28 43.02 46.44 48.20 48.59 48.63 50.16 51.66 51.83 52.03 53.62 54.01 55.04 49.89 51.14 19.96 20.93 32.03 35.80 36.72
Goodwill 23.97 23.56 23.80 23.95 23.17 22.45 22.37 22.55 22.10 21.70 21.89 21.49 22.00 28.61 28.54 17.06 17.51 26.14 27.37 27.49
Other assets 6.32 5.21 4.58 4.31 4.01 3.81 3.52 3.55 3.33 3.19 3.25 3.18 3.22 2.63 2.68 2.89 2.57 2.82 2.78 2.76
Long-term assets 75.50% 75.61% 78.69% 80.31% 79.49% 78.51% 79.68% 81.49% 80.94% 80.55% 82.43% 82.35% 83.95% 84.62% 85.78% 43.25% 44.43% 66.07% 73.57% 74.61%
Total assets 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. AbbVie Inc. current assets as a percentage of total assets increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Property and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. AbbVie Inc. property and equipment, net as a percentage of total assets decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Long-term assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. AbbVie Inc. long-term assets as a percentage of total assets decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.